Plain-English translation of NCT06662071 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Bladder cancer often comes back after surgery, even in early stages. This trial is testing a new approach using organoid technology—growing a tiny sample of your tumor in the lab to see which chemotherapy drugs work best against it—then using those specific drugs to rinse your bladder. The goal is to reduce the chance of your cancer returning compared to standard treatments like BCG instillation.
Current bladder cancer prevention treatments like BCG work well for some patients but can cause serious side effects that make people stop treatment. This trial is exploring whether personalizing the medication based on each person's individual tumor could be more effective and better tolerated.
You likely qualify if…
You likely don't qualify if…
If you join this trial, a small sample of your tumor will be grown in the lab to test which chemotherapy drugs work best against your cancer. You will then be randomly assigned to receive one of three treatments: personalized chemotherapy drugs based on your tumor's test results, standard BCG bladder instillation, or a control medication. The treatment will be delivered directly into your bladder through a catheter during clinic visits, and you will be monitored for side effects and cancer recurrence over time.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China